Scandinavian ChemoTech AB (publ)

Stockholm Stock Exchange CMOTEC-B.ST

Scandinavian ChemoTech AB (publ) EBITDA for the year ending December 31, 2023: USD -1.93 M

Scandinavian ChemoTech AB (publ) EBITDA is USD -1.93 M for the year ending December 31, 2023, a 2.75% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Scandinavian ChemoTech AB (publ) EBITDA for the year ending December 31, 2022 was USD -1.99 M, a -6.01% change year over year.
Scandinavian ChemoTech AB (publ) EBITDA for the year ending December 31, 2021 was USD -1.87 M, a -43.57% change year over year.
Scandinavian ChemoTech AB (publ) EBITDA for the year ending December 31, 2020 was USD -1.31 M, a -2.13% change year over year.
Scandinavian ChemoTech AB (publ) EBITDA for the year ending December 31, 2019 was USD -1.28 M, a -41.40% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Stockholm Stock Exchange: CMOTEC-B.ST

Scandinavian ChemoTech AB (publ)

CEO	Mr. Stefan Mohan Frick
IPO Date	Dec. 6, 2016
Location	Sweden
Headquarters	Medicon Village
Employees	6
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.

Key trends

Past 5 years